A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: The MaxCmin2 trial

Antiviral Therapy

Volumn 10, Issue 6, 2005, Pages 735-743

  Dragsted, Ulrik B ^a   Gerstoft, Jan ^b   Youle, Mike ^c   Fox, Zoe ^a   Losso, Marcello ^d   Benetucci, Jorge ^e   Jayaweera, Dushyantha T ^f   Rieger, Armin ^g   Bruun, Johan N ^h   Castagna, Antonella ⁱ   Gazzard, Brian ^j   Walmsley, Sharon ^k   Hill, Andrew ^l   Lundgren, Jens D ^a  

^a HVIDOVRE HOSPITAL   (Denmark)

^b Rigshospitalet   (Denmark)

^c ROYAL FREE HOSPITAL   (United Kingdom)

^d HOSPITAL RAMOS MEJÍA   (Argentina)

^e HOSPITAL F J MUÑIZ   (Argentina)

^f UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^g MEDICAL UNIVERSITY OF VIENNA   (Austria)

^h ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

ⁱ SAN RAFFAELE HOSPITAL   (Italy)

^j Chelsea and Westminster Healthcare   (United Kingdom)

^k UNIVERSITY HEALTH NETWORK   (Canada)

^l UNIVERSITY OF LIVERPOOL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

LOPINAVIR PLUS RITONAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG FORMULATION; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; FEMALE; GASTROINTESTINAL DISEASE; GEL; HEPATOBILIARY DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE;

EID: 25444471854     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Moyle GJ & Back D. Principles and practice of HIV-protease inhibitor pharmacoenhancement. HIV Medicine 2001; 2:105-113.
2. Burger DM, Hoetelmans RM, Hugen PW, Mulder JW, Meenhorst PL, Koopmans PP, Brinkman K, Keuter M, Dolmans W & Hekster YA. Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1-infected patients on indinavir-containing triple therapy. Antiviral Therapy 1998; 3:215-220.
3. Durant J, Clevenbergh P, Garraffo R, Halfon P, Icard S, Del Giudice P, Montagne N, Schapiro JM & Dellamonica P. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: Pharmacological data from the Viradapt Study. AIDS 2000; 14:1333-1339.
4. Walmsley S, Bernstein B, King M, Arribas J, Beall G, Ruane P, Johnson M, Johnson D, Lalonde R, Japour A, Brun S & Sun E; M98-863 Study Team. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. New England Journal of Medicine 2002; 346:2039-2046.
5. Martinez E, Domingo P, Galindo MJ, Milinkovic A, Arroyo JA, Baldovi F, Larrousse M, Leon A, de Lazzari E & Gatell JM. Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir. Clinical Infectious Diseases 2004; 38:1017-1023.
6. Friis-Moller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, Thiebaut R, Morfeldt L, De Wit S, Pradier C, Calvo G, Law MG, Kirk O, Phillips AN & Lundgren JD; Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. New England Journal of Medicine 2003; 349:1993-2003.
7. Dragsted UB, Gerstoft J, Pedersen C, Peters B, Duran A, Obel N, Castagna A, Cahn P, Clumeck N, Bruun JN, Benetucci J, Hill A, Cassetti I, Vernazza P, Youle M, Fox Z & Lundgren JD; MaxCmin1 Trial Group. Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial. The Journal of Infectious Diseases 2003; 188:635-642.
8. Kurowski M, Sternfeld T, Hill A & Moecklinghoff C. Comparative pharmacokinetics and short-term safety of twice daily (BID) fortovase/ritonavir and invirase/ritonavir, 9th Conference on Retroviruses and Opportunistic Infections 24-28 February 2002, Seattle, USA. Abstract 432-W
9. Kirk O, Pedersen C, Law M, Gulick RM, Moyle G, Montaner J, Eron JJ Jr, Phillips AN & Lundgren JD. Analysis of virological efficacy in trials of antiretroviral regimens: drawbacks of not including viral load measurements after premature discontinuation of therapy. Antiviral Therapy 2002; 7:271-281.
10. Biostatistical methodology in clinical trials in applications for marketing authorizations for medicinal products. CPMP Working Party on Efficacy of Medicinal Products Note for Guidance III/3630/92-EN. Statistics in Medicine 1995; 14:1659-1682.
11. Pozniak A, Gazzard B, Anderson J, Babiker A, Churchill D, Collins S, Fisher M, Johnson M, Khoo S, Leen C, Loveday C, Moyle G, Nelson M, Peter B, Phillips A, Pillay D, Wilkins E, Williams I, Yuole M; BHIVA Writing Committee BHIVA Executive Committee. British HIV association (BHIVA) guidelines for the treatment of hiv-infected adults with antiretroviral therapy. HIV Medicine 2003; 4(Suppl 1):1-41.
12. Lee GA, Seneviratne T, Noor MA, Lo JC, Schwarz JM, Aweeka FT, Mulligan K, Schambelan M & Grunfeld C. The metabolic effects of lopinavir/ritonavir in HIV-negative men. AIDS 2004; 18:641-649.